Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | VCP | P55072 | 6/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | PTGIR | P43119 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29586994 | 0.80 | LMNA (0.36) | LMNA | |
| SCHEMBL28455598 | 0.73 | EHMT2 (0.48) | PDGFRBPDGFRAMAPTALDH1A1MAOA | |
| SCHEMBL12949631 | 0.73 | EHMT2 (0.48) | PDGFRBPDGFRAMAPTALDH1A1MAOA | |
| SCHEMBL15271760 | 0.73 | EHMT2 (0.48) | PDGFRBPDGFRAMAPTALDH1A1MAOA | |
| SCHEMBL9175317 | 0.73 | CNR1 (0.39) | MAPTALDH1A1LMNATSHR | |
| SCHEMBL28283901 | 0.73 | NPC1 (0.44) | MAPTALDH1A1LMNATSHR | |
| SCHEMBL15271518 | 0.71 | EHMT2 (0.50) | PDGFRBPDGFRAMAPTALDH1A1TSHR | |
| SCHEMBL10834649 | 0.68 | MAOA (0.47) | PDGFRBPDGFRAALDH1A1MAOAMAOB | |
| SCHEMBL12949394 | 0.67 | KDM4E (0.42) | PDGFRBPDGFRAMAPTALDH1A1MAOA | |
| SCHEMBL11546966 | 0.67 | PDGFRB (0.38) | PDGFRBPDGFRAALDH1A1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3592729-B1 | CATALYTIC C-X-BOND METATHESIS THROUGH ARYLATION | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2021-06-30 | — | — | EP | disclosed |
| EP-3592729-B1 | CATALYTIC C-X-BOND METATHESIS THROUGH ARYLATION | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2021-06-30 | — | — | EP | disclosed |
| US-20210130286-A1 | CATALYTIC C-X-BOND METATHESIS THROUGH ARYLATION | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2021-05-06 | — | — | US | disclosed |
| US-20210130286-A1 | CATALYTIC C-X-BOND METATHESIS THROUGH ARYLATION | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130286-A1 | CATALYTIC C-X-BOND METATHESIS THROUGH ARYLATION | AOX1, TYR, CXXC4 | PDGFRB 4527/4885PDGFRA 4006/4885MAPT 1811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.